

How Prepared are we to Control Severe Acute Respiratory Syndrome in Future

Kanchan Bhardwaj

Department of Pediatrics,
All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India

Received 2012-12-01, Revised 2012-12-10; Accepted 2013-07-20

ABSTRACT

No non-human reservoirs for smallpox- and polio-viruses has contributed to the success of worldwide eradication of smallpox and a significant control of poliomyelitis. Most emerging and re-emerging viruses including SARS Coronavirus (SARS-CoV), have animal reservoirs and therefore, they impose a constant threat of host jump leading to outbreaks in humans. It is desirable to be ready for control of infections that are caused by zoonotic pathogens, even after an outbreak has ended. This literature review is a compilation of advances made so far for diagnosis and treatment of SARS.

Keywords: SARS Coronavirus (SARS-CoV), Antivirals, Vaccines, Human Monoclonal Antibody

1. INTRODUCTION

According to the World Health Organization, there were 8,098 reported cases and 774 deaths worldwide during the Severe Acute Respiratory Syndrome (SARS) outbreak in 2002-2003. First case of SARS appeared in November 2002 in Guangdong Province, China. By April 2003, it had spread to around 30 countries including, Vietnam, Hong Kong, Singapore, Taiwan, India, Canada and United States of America.

On 24th March 2003, Center for Disease Control and Prevention, Atlanta, USA announced that the possible etiologic agent of SARS is either a human metapneumovirus or a previously unrecognized coronavirus. Shortly, it was confirmed to be a novel coronavirus based on electron microscopy, immunostaining, seroconversion as well as RT-PCR and sequencing of polymerase gene fragment (Drosten *et al.*, 2003; Ksiazek *et al.*, 2003). Availability and affordability of DNA sequencing facilitated genotyping of several isolates of SARS-CoV. By 29th April 2003, complete genome sequences of SARS-CoV isolates, Tor2, Urbani, HKU-39849, CUHK-W1 and KYK were posted on the web. Facilities at the BCCA Genome Sciences Centre in Vancouver, Centers for Disease Control and Prevention in Atlanta, University of Hong

Kong, Chinese University of Hong Kong, Genome Institute of Singapore and Beijing Genomics Institute were involved in this seminal work. Many others are also sequenced and compared subsequently. The information obtained from such analyses was of epidemiologic significance. One, it revealed mutability of SARS-CoV, which, would have implications in vaccine development (Ruan *et al.*, 2003; Tsui *et al.*, 2003). Second, it led to the understanding that the organization of SARS-CoV genome is similar to the other coronaviruses although, at the primary sequence level, they were only distantly related (Rota *et al.*, 2003). This ruled out the possibility of simple recombination event(s) among existing coronaviruses being responsible for the emergence of SARS-CoV. It was also indicative of the fact that this virus might have originated from animals. In fact, virus isolated from SARS patients was able to cause a similar disease in cynomolgus macaques (Fouchier *et al.*, 2003). Scientists began a search for the source of the SARS-CoV by scanning wild and domestic animals and indeed found SARS virus-like coronaviruses from Himalayan palm civets and a raccoon dog found in a market in Guangdong, China. From sequence analysis, it was apparent that the viruses of human and civet origin shared more than 99% homology. However, phylogenetic analysis of S proteins, placed viruses of

human and civet origin in separate clusters. Also, the animal isolates contained a 29-nucleotide sequence in ORF 8 region that was absent in most human isolates (Guan *et al.*, 2003). These analyses and the fact that palm civets did not show a widespread infection indicated that palm civets might not have been the natural reservoir host for SARS-CoV. Instead, they may have only served a medium to facilitate animal-to-human transition. This led to further searches in other animals including bats, rodents and monkeys for SARS-CoV host. SARS-CoV like viruses were found in bats. Sequence analysis showed that there was a significant homology between bat and human viruses. Interestingly, the 29-nucleotides in the ORF-8 was present in the virus of bat origin and the most variability between the two was found to be in the S1 region of spike protein, which is responsible for receptor binding (Li *et al.*, 2005a). Findings from all such studies were put together to establish origin of SARS-CoV. The most accepted theory is that bats are the natural reservoirs of SARS-CoV. Civets and other wild animals came in contact with SARS-CoV infected bats in a market, where they acquired the virus. It evolved in these animals before hopping to humans. Major species-specific determinants are traced to the viral S protein.

Even after the outbreak came under control, scientists around the world continued to treat the situation as urgent and have made significant advances in understanding the SARS-CoV biology, developing diagnostics, identifying a number of drug targets, potential antivirals, tools for vaccines and immunotherapy for SARS.

1.1. Diagnostics

Early and sensitive detection of SARS-CoV is important not only for treatment but also for control of disease spread. Initially, clinical symptoms and epidemiologic linkage were diagnostics for SARS followed by serologic testing, viral culture and PCR-based methods (Wu *et al.*, 2003; Yam *et al.*, 2003). Now, reagents are also available for Nucleocapsid (N) protein and Spike (S) protein detection (Che *et al.*, 2004; Sunwoo *et al.*, 2012).

1.2. Antivirals

During the outbreak, spread of SARS-CoV was predominantly controlled by surveillance and quarantine. Agents that were usually adapted for treatment were ribavirin, corticosteroids, human interferons (IFN- β and IFN- γ) and convalescent plasma (Barnard *et al.*, 2004; He *et al.*, 2004; Keyaerts *et al.*, 2004; Wu *et al.*, 2004a;

Cinatl *et al.*, 2005; Groneberg *et al.*, 2005; Lai, 2005; Morgenstern *et al.*, 2005; Saijo *et al.*, 2005; Lau *et al.*, 2006; Stockman *et al.*, 2006). However, a systematic review of clinical trials and *in vitro* studies revealed that although agents such as ribavirin, corticosteroids, lopinavir and type I interferon showed inhibition of SARS-CoV in tissue culture, their usefulness was inconclusive in most patient studies (Stockman *et al.*, 2006). Some studies have in fact shown possible harm from some of them (Lau *et al.*, 2006; Stockman *et al.*, 2006). Since then, several other small molecules have been investigated for effect on SARS-CoV *in vitro* and are listed with their observed effects in **Table 1**. In addition, progress made in understanding cellular and biochemical processes of the virus has allowed the identification of several novel antiviral targets and molecules to inhibit them.

1.3. Entry Inhibitors

Three important steps for SARS viral entry into the host cell include its binding to the host cells through an interaction between viral spike protein (S protein) and its receptor, the angiotensin-converting enzyme 2 (ACE 2) followed by conformational changes in the S protein and its activation by proteolysis. Agents that target these steps have been identified and analyzed for their inhibitory effects on SARS-CoV entry. Classes of entry inhibitor include siRNA to spike protein gene (Qin *et al.*, 2004), peptides or recombinant proteins derived from S protein (Ni *et al.*, 2005; Sainz *et al.*, 2006; Ujike *et al.*, 2008; Struck *et al.*, 2012) or ACE2 (Imai *et al.*, 2005; Han *et al.*, 2006), small molecules that bind S protein (Yi *et al.*, 2004) and inhibitors of cellular protease (Simmons *et al.*, 2005; Wang *et al.*, 2007; Zhou *et al.*, 2011). In addition, TNF- α Converting Enzyme (TACE) and lactoferrin bound to heparin sulfate proteoglycans have also been identified as targets for inhibition of viral entry (Haga *et al.*, 2010; Lang *et al.*, 2011).

1.4. Viral Protease Inhibitors

SARS viral replicase polyprotein is proteolytically processed by the viral proteases to generate functional enzymes. Owing to their essential role, 3CL protease, the main protease and the Papain-Like Protease (PLP2) of SARS-CoV are considered important drug targets. Based on homology modeling using crystal structures for human coronavirus and an inhibitor complex of porcine coronavirus, Anand *et al.* (2003) proposed that rhinovirus 3C protease inhibitors might be modified for inhibiting SARS protease (Anand *et al.*, 2003; Regnier *et al.*, 2009).

Table 1. Effect of antiviral agents on SARS-CoV *in vitro*

Agent	Major effects reported
Calpain	A class of cellular cysteine proteinases that inhibited SARS virus yield with an effective concentration in micro molar range (Barnard <i>et al.</i> , 2004)
Niclosamide	An existing antihelminthic drug that abolished viral antigen synthesis at concentration of 1.56 μ M (Wu <i>et al.</i> , 2004b)
Aurintricarboxylic Acid (ATA)	ATA is known to inhibit protein and nucleic acid interaction. It was reported to be 10 or 100 times more potent inhibitor of SARS-CoV than IFN- α and IFN- β , respectively (He <i>et al.</i> , 2004)
Chloroquine	A clinically approved drug for malaria was effective with an IC50 in lower μ M range (Keyaerts <i>et al.</i> , 2004). In addition to its effect through elevation of endosomal pH, chloroquine seems to interfere with terminal glycosylation of ACE2, the the receptor for SARS-CoV (Vincent <i>et al.</i> , 2005)
Nitric oxide	Nitric oxide donor S-nitroso-N-acetylpenicillamine inhibited SARS-CoV by 2 logs at 100 μ M (Akerstrom <i>et al.</i> , 2005)
Hydrocortisone	Only at very high concentrations, hydrocortisone showed a moderate effect on chemokine production by SARS-CoV (Cinatl <i>et al.</i> , 2005)
Procyanidins and butanol extracts of cinnamomi cortex	A moderate inhibitory activity in wild-type SARS-CoV and HIV/SARS-CoV pseudovirus assay is reported (Zhuang and Jiang, 2009)
Synthetic peptides outside of spike protein heptad	S protein fragments spanning sequence variation hotspots reduced SARS-CoV infectivity significantly (Guan <i>et al.</i> , 2003)
Dipeptide glutaminyl fluoromethyl ketone	An inhibition with EC50 value in low μ molar range is observed (Zhang <i>et al.</i> , 2008)
Cyclopentenyl carbocyclic nucleosides	1,2,3-trizole analogs which, exhibited an antiviral activity with an EC50 of 21 μ M or 47 μ M (Cho and Bernard, 2006)
Indomethacin	Inhibits viral RNA synthesis with > 1,000 fold reduction in CCoV infected dogs (Amici <i>et al.</i> , 2006)
Phenanthroindolizines	Tylophorine compounds inhibited SARS-CoV with EC50 in nM range (Yang <i>et al.</i> , 2010)
Emodin	Emodin is shown to inhibit SARS-CoV via its ion channel protein, 3a (Schwarz and Wang, 2011)
Glycyrrhizin	Glycyrrhizin inhibits SARS but some of its derivatives showed reduced specificity (Hoever and Baltina, 2005)
Antisense Peptide Nucleic Acids (PNAs)	PNAs that were targeted to interfere with programmed -1 ribosomal shifting and fused to cell penetrating peptides resulted in inhibition of SARS-CoV replication with IC50 of 4.4 μ M (Ahn <i>et al.</i> , 2011)
Antisense morpholino oligomers	Oligomers targeted to Transcription-Regulatory Sequence (TRS) are reported to show a low inhibitory activity against SARS-CoV (Neuman <i>et al.</i> , 2005)
SiRNA	siRNAs for various targets including, interferons, leader sequence or N protein have been tested (Li <i>et al.</i> , 2005a; 2005b; Wu and Huang, 2005; Zhao and Qin, 2005; Tang and Li, 2008)

Homology modeling also formed a basis for designing mechanism-based irreversible inhibitors of 3CLpro with an activity of wide spectrum across coronaviruses (Yang *et al.*, 2005a). Besides, several groups have identified a number of inhibitors of 3CLpro using a variety of approaches. Virtual screening (Plewczynski *et al.*, 2007; Mukherjee *et al.*, 2008; 2011; Nguyen *et al.*, 2011) or a high-throughput screening of small molecule libraries have identified inhibitors including an anti-HIV agent and serotonin antagonist, cinanserin (Blanchard *et al.*, 2004; Kao *et al.*, 2004; Wu *et al.*, 2004a; Chen *et al.*, 2005). Other

3CL protease inhibitors identified so far belong to categories such as plant derived phenolic or flavonoid compounds (Lin *et al.*, 2005; Nguyen *et al.*, 2012), active site, non-active site or competitive inhibitors (Kaeppler *et al.*, 2005; Lee *et al.*, 2005; Du *et al.*, 2007; Ryu *et al.*, 2010), ketones or ester based inhibitors (Goetz *et al.*, 2007; Zhang *et al.*, 2007; Ghosh *et al.*, 2008; Shao *et al.*, 2008; Verschuere *et al.*, 2008; Zhang *et al.*, 2008), modified peptidomimetic inhibitors (Ghosh *et al.*, 2007), metal conjugated inhibitors (Lee *et al.*, 2007; 2009), common inhibitors of Corona and Picornaviruses

(Kuo *et al.*, 2009) and pyrimidines (Ramajayam *et al.*, 2010). Protease inhibitors have also been reviewed elsewhere (Liang, 2006; Ramajayam *et al.*, 2011).

In addition to its role in proteolytic processing of the viral polymerase, PLP2 is also involved in host evasion. Some of the first identified small molecule lead compounds for inhibition of PLP2 were thiopurine analogs (Chou *et al.*, 2008; Chen *et al.*, 2009). Besides, Ratia *et al.* (2008) have synthetically evolved a noncovalent inhibitor demonstrating an IC₅₀ of around 15 μ M in a cell based SARS-CoV replication assay (Ratia *et al.*, 2008). Dooley *et al.* (2006) and Ghosh *et al.* (2009) have identified small molecules with EC₅₀ values in lower micromolar range (Dooley *et al.*, 2006; Ghosh *et al.*, 2009). Recently, a yeast-based assay for measurement of papain-like protease activity that is suitable for screening of inhibitors was established (Frieman *et al.*, 2011).

1.5. Helicase Inhibitors

Bismuth complexes and RNA aptamers have been shown to inhibit activity of SARS-CoV helicase (Yang *et al.*, 2007; Jang *et al.*, 2008; Adedeji *et al.*, 2012; Keum and Jeong, 2012).

1.6. Host Pathway Inhibitors

Although, inhibitors of viral proteins have been used for treating some other viral infections, a significant issue with targeting the viral proteins has been the development of drug resistant virus. This is likely due to the selection of mutant virus under drug pressure. Inhibitors of host systems, including immune and housekeeping, that may be critical for virus survival are alternatives that are worth an investigation. Cyclosporine and FK506 have emerged as examples of such inhibitors (De Wilde *et al.*, 2011; Pfefferle *et al.*, 2011; Carbajo-Lozoya *et al.*, 2012). Other host pathway proteins that are potential antiviral drug targets have been identified (Ma *et al.*, 2010; Bhardwaj *et al.*, 2012; Millet *et al.*, 2012; Smith *et al.*, 2012; Zhao *et al.*, 2012).

1.7. Vaccines and Immunotherapy for SARS-CoV

Coronaviruses cause significant infections in humans and animals. Although, no vaccines against coronaviruses are available at this time for use in human, they are produced for use in animals (Olsen *et al.*, 1993; Anton *et al.*, 1996). A need for prophylactic treatment or a vaccine is underscored by what happened during the 2002-2003 SARS outbreak. In the Vietnamese outbreak of SARS, all patients who died apart from the index

patient were healthcare professionals including a WHO scientist, Dr. Carlo Urbani. It was Dr. Urbani's initiatives that led to the successful containment of the disease in Hanoi. He died of SARS on March 29th 2003.

Roberts *et al.* (2008) and Roper and Rehm (2009) have reviewed the SARS animal models and the initial vaccine studies in great detail (Roberts *et al.*, 2008; Roper and Rehm, 2009). Several animal models that have been developed for SARS vaccine studies include mice, African green monkey, ferrets, macaques, hamsters and Chinese masked palm civet. Multiple lab have demonstrated the feasibility of various types of vaccines (**Table 2**). However, vaccine efficacy and safety issues are still being investigated (**Table 2**). Studies related to SARS vaccine have taught us several lessons about pathogenesis and host responses to SARS-CoV, in addition to unraveling the need for caution. With certain experimental vaccines, such as the viral vector based ones, immunopathology and redirection of the viral vector to brain was reported (Czub *et al.*, 2005; Deming *et al.*, 2006; Kam *et al.*, 2007; Jaume *et al.*, 2011; Tseng *et al.*, 2012). Subsequent studies demonstrated that a sub lingual immunization can prevent the viral vector entry into the brain (Shim *et al.*, 2012). Also, an intranasal route of vaccination was shown to protect mice from SARS-CoV challenge better than an intramuscular delivery of the same vaccine (See *et al.*, 2006; Hu *et al.*, 2007). Expression of full length S protein is shown to result in enhanced hepatitis or infection whereas, expression of just the ectodomain of S protein eliminated infection enhancement (Weingartl *et al.*, 2004; Yang *et al.*, 2005b). All these reports point to that it will be important to establish an appropriate combination of vaccination route, vaccine vector and choice of epitopes for each vaccine type. SARS vaccines that generate a predominantly cellular or a predominantly humoral response, as well as therapeutic monoclonal antibodies, have been shown protective effects in animal models. Therefore, what kind of responses are important for protection has not been clear (Subbarao *et al.*, 2004; Zakhartchouk *et al.*, 2005; Lin *et al.*, 2007; See *et al.*, 2008; Zhao and Perlman, 2010). Cameron *et al.* (2012) have recently reported an analysis of transcripts expressed during SARS-CoV infection in vaccination and reinfection trials in ferrets (Cameron *et al.*, 2012). Such studies can potentially reveal new therapeutic options in addition to providing the basic understanding of host responses during infection, vaccination and re-infection.

Table 2. Experimental vaccines for SARS

Vaccine type	Safety	Efficacy
Inactivated virus	Safe and immunogenic in humans (Lin <i>et al.</i> , 2007). Hypersensitive reaction upon post-immunization viral challenge in mice (Kam <i>et al.</i> , 2007; Tseng <i>et al.</i> , 2012)	Efficacy needs to be established in appropriate animal model (See <i>et al.</i> , 2008)
Recombinant vector Vaccines (Adenovirus, Poxvirus or recombinant)	Disease exacerbation upon SARS-CoV challenge in some cases (Czub <i>et al.</i> , 2005)	Protective in mice, ferrets, monkeys, hamsters (Bukreyev <i>et al.</i> , 2004; See <i>et al.</i> , 2006; Napoli <i>et al.</i> , 2007; See <i>et al.</i> , 2008)
Subunit or virus like particle vaccines	Immunopathology is observed in some cases (Kam <i>et al.</i> , 2007; Jaume <i>et al.</i> , 2011; Tseng <i>et al.</i> , 2012). Hypersensitive reaction upon post-immunization viral challenge in mice (Kam <i>et al.</i> , 2007; Tseng <i>et al.</i> , 2012)	Protective in hamsters and ferrets (Kam <i>et al.</i> , 2007; Tseng <i>et al.</i> , 2012)
DNA vaccines	Safe and immunogenic in healthy humans (Martin <i>et al.</i> , 2008). Hypersensitive reaction upon post-immunization viral challenge in mice (Kam <i>et al.</i> , 2007; Tseng <i>et al.</i> , 2012)	Protective in mice (Yang <i>et al.</i> , 2004)
Attenuated vaccines	Safety needs to be established	E protein lacking-or ExoN mutant vaccine is immunogenic and efficacious (Lamirande <i>et al.</i> , 2008; Graham <i>et al.</i> , 2012)

2. CONCLUSION

Although, a myriad of compounds have been identified to show inhibitory effects on SARS-CoV *in vitro*, only a few of those are reported for their safety and efficacy in animal models. Of the tested compounds, a hybrid interferon alpha (IFN- α) and an IFN- inducer, a mismatch double stranded RNA, have shown potent inhibition of SARS-CoV replication in the lungs of infected mice (Barnard *et al.*, 2006). It would be useful and desirable to evaluate the other compounds in animal models for their safety and efficacy. With identification of epitopes that will not generate antibodies cross-reactive to self-antigens and care taken to eliminate antibody dependent enhancement of disease, therapeutic use of human monoclonal antibodies seems a promising option for SARS. Coughlin and Prabhakar (2012) have reviewed the human monoclonal antibodies generated for anti-SARS therapy (Coughlin and Prabhakar 2012). For active immunization, efficacy of the developed vaccines needs to be established in a most relevant disease model. Efforts have gone into improving animal models for SARS; however, they still have limitation.

A novel SARS-like human coronavirus, HCoV-EMC/2012 was identified earlier this year (Lu and Liu, 2012; Boheemen *et al.*, 2012). Although, HCoV-EMC/2012 is only distantly related to SARS-CoV, the knowledge and reagents acquired from SARS-CoV

research may prove useful in understanding and controlling this novel and other coronavirus (Elshabrawy *et al.*, 2012; Graham *et al.*, 2012).

3. ACKNOWLEDGMENT

I acknowledge Dr. Ranjith-Kumar C.T of Translational Health Science and Technology Institute, Gurgaon, India and Dr. Ramesh Agarwal of All India Institute of Medical Sciences, New Delhi, India for editing the manuscript.

4. REFERENCES

- Adedeji, A.O., K. Singh, K. Singh, N.E. Calcaterra and M. L. DeDiego *et al.*, 2012. Severe acute respiratory syndrome coronavirus replication inhibitor that interferes with the nucleic acid unwinding of the viral helicase. *Antimicrob. Agents Chemotherapy*, 56: 4718-4728. DOI: 10.1128/AAC.00957-12
- Ahn, D.G. and W. Lee, J.K. Choi, S.J. Kim E.P. Plant and F. Almazan, 2011. Interference of ribosomal frameshifting by antisense peptide nucleic acids suppresses SARS coronavirus replication. *Antiviral Res.*, 91: 1-10. DOI: 10.1016/j.antiviral.2011.04.009
- Akerstrom, S., M. Mousavi-Jazi, J. Klingström, M. Leijon and A. Lundkvist *et al.*, 2005. Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus. *J. Virol.*, 79: 1966-1969. DOI: 10.1128/JVI.79.3.1966-1969.2005

- Amici, C. and A.D. Coro, A. Ciucci and L. Chiappa 2006. Indomethacin has a potent antiviral activity against SARS coronavirus. *Antiviral Therapy*, 11: 1021-1030. PMID: 17302372
- Anand, K., J. Ziebuhr, P. Wadhvani, J.R. Mesters and R. Hilgenfeld *et al.*, 2003. Coronavirus main proteinase (3CL^{pro}) structure: Basis for design of anti-SARS drugs. *Science*, 300: 1763-1767. DOI: 10.1126/science.1085658
- Anton, I.M., S. Gonzalez, M.J. Bullido, M. Corsin and C. Risco *et al.*, 1996. Cooperation between Transmissible Gastroenteritis Coronavirus (TGEV) structural proteins in the in vitro induction of virus-specific antibodies. *Virus Res.*, 46: 111-124. DOI: 10.1016/S0168-1702(96)01390-1
- Barnard, D. L., V. D. Hubbard, J. Burton, D.F. Smee and J.D. Morrey *et al.*, 2004. Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and beta-D-N4-hydroxycytidine. *Antivir. Chem. Chemother.*, 15: 15-22. PMID: 15074711
- Barnard, D.L., C.W. Day, K. Bailey, M. Heiner and R. Montgomery, *et al.*, 2006. Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice. *Antivir. Chem. Chemother.*, 17: 275-284. PMID: 17176632
- Bhardwaj, K., P. Liu, J.L. Leibowitz and C.C. Kao, 2012. The coronavirus endoribonuclease Nsp15 interacts with retinoblastoma tumor suppressor protein. *J. Virol.*, 86: 4294-4304. DOI: 10.1128/JVI.07012-11
- Blanchard, J.E., N.H. Elowe, C. Huitema, P.D. Fortin and J.D. Cechetto *et al.*, 2004. High-throughput screening identifies inhibitors of the SARS coronavirus main proteinase. *Chem. Biol.*, 11: 1445-1453. DOI: 10.1016/j.chembiol.2004.08.011
- Boheemen, S.V., M.D. Graaf, C. Lauberb, T.M. Bestebroera and V.S. Raja *et al.*, 2012. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. *mBio*, 3: e00473-e00473. DOI: 10.1128/mBio.00473-12
- Bukreyev, A., E.W. Lamirande, U.J. Buchholz, L.N. Vogel and W.R. Elkins *et al.*, 2004. Mucosal immunisation of African green monkeys (*Cercopithecus aethiops*) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. *Lancet*, 363: 2122-2127. DOI: 10.1016/S0140-6736(04)16501-X
- Cameron, M.J., A.A. Kelvin, C.M. Cameron, L. Ran and S.G. Paquette *et al.*, 2012. Lack of Innate Interferon Responses during SARS coronavirus infection in a vaccination and reinfection ferret model. *PloS One*, 7: e45842-e45842.
- Carbajo-Lozoya, J., M.A. Muller, S. Kallies, V. Thiel and C. Drosten *et al.*, 2012. Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506. *Virus Res.*, 165: 112-117. DOI: 10.1016/j.virusres.2012.02.002
- Che, X.Y., W. Hao, Y. Wang, Y.C. Xu and C.S. Feng *et al.*, 2004. Nucleocapsid protein as early diagnostic marker for SARS. *Emerg. Infect. Dis.*, 10: 1947-1949. DOI: 10.3201/eid1011.040516
- Chen, L., C. Gui, X. Luo, Q. Yang and S. Gunther *et al.*, 2005. Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro. *J. Virol.*, 79: 7095-7103. DOI: 10.1128/JVI.79.11.7095-7103.2005
- Chen, X., C.Y. Chou and G.G. Chang, 2009. Thiopurine analogue inhibitors of severe acute respiratory syndrome-coronavirus papain-like protease, a deubiquitinating and deISGylating enzyme. *Antivir. Chem. Chemother.*, 19: 151-156. PMID: 19374142
- Cho, J.H. and D.L. Bernard, 2006. Synthesis of cyclopentenyl carbocyclic nucleosides as potential antiviral agents against orthopoxviruses and SARS. *J. Med. Chem.*, 49: 1140-1148. DOI: 10.1021/jm0509750
- Chou, C.Y., C.H. Chien, Y.S. Han M.T. Prebanda and H.P. Hsieh *et al.*, 2008. Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus. *Biochem. Pharmacol.*, 75: 1601-1609. DOI: 10.1016/j.bcp.2008.01.005
- Cinatl, J. Jr., C.J., M. Michaelis, M. Michaelis, G. Hoever and W. Preiser *et al.*, 2005. Development of antiviral therapy for severe acute respiratory syndrome. *Antivir. Res.*, 66: 81-97. DOI: 10.1016/j.antiviral.2005.03.002
- Coughlin, M.M. and B.S. Prabhakar, 2012. Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: Target, mechanism of action and therapeutic potential. *Rev. Med. Virol.*, 22: 2-17. DOI: 10.1002/rmv.706
- Czub, M., H. Weingartl, S. Czub, R. He and J. Cao *et al.* 2005. Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets. *Vaccine*, 23: 2273-2279. DOI: 10.1016/j.vaccine.2005.01.033

- De Wilde, A.H., J.C. Zevenhoven-Dobbe, Y.V.D. Meer, V. Thiel and K. Narayanan *et al.*, 2011. Cyclosporin A inhibits the replication of diverse coronaviruses. *J. General Virol.*, 92: 2542-2548. DOI: 10.1099/vir.0.034983-0
- Deming, D., T. Sheahan, M. Heise, B. Yount and N. Davis *et al.*, 2006. Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. *PLoS Med.*, 3: e525-e525. DOI: 10.1371/journal.pmed.0030525
- Dooley, A.J., N. Shindo, B. Taggart, J.G. Park and Y.P. Pang *et al.*, 2006. From genome to drug lead: Identification of a small-molecule inhibitor of the SARS virus. *Bioorganic Med. Chem. Lett.*, 16: 830-833. PMID: 16325400
- Drosten, C., S. Gunther, W. Preiser, S.V.D. Werf and H.R. Brodt *et al.*, 2003. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. *New England J. Med.*, 348: 1967-1976. DOI: 10.1056/NEJMoa030747
- Du, Q.S., H. Sun and K.C. Chou, 2007. Inhibitor design for SARS coronavirus main protease based on "Distorted key theory". *Med. Chem.*, 3: 1-6. DOI: 10.2174/157340607779317616
- Elshabrawy, H.A., M.M. Coughlin, S.C. Baker and B.S. Prabhakar, 2012. Human Monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing. *PLoS One*, 7: e50366-e50366. DOI: 10.1371/journal.pone.0050366
- Fouchier, R.A., T. Kuiken, Martin Schutten, G.V. Amerongen and K. Stohr *et al.*, 2003. Aetiology: Koch's postulates fulfilled for SARS virus. *Nature*, 423: 240-240. DOI: 10.1038/423240a
- Frieman, M., D. Basu, K. Matthews, J. Taylor and G. Jones *et al.*, 2011. Yeast based small molecule screen for inhibitors of SARS-CoV. *PLoS One*, 6: e28479-e28479. DOI: 10.1371/journal.pone.0028479
- Ghosh, A.K., G. Gong, V. Grum-Tokars, D.C. Mulhearn and S.C. Baker *et al.*, 2008. Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors. *Bioorganic Med. Chem. Lett.*, 18: 5684-5688. DOI: 10.1016/j.bmcl.2008.08.082
- Ghosh, A.K., J. Takayama, Y. Aubin, K. Ratia and R. Chaudhuri *et al.*, 2009. Structure-Based design, synthesis and biological evaluation of a series of novel and reversible inhibitors for the severe acute respiratory syndrome-coronavirus papain-like protease. *J. Med. Chem.*, 52: 5228-5240. DOI: 10.1021/jm900611t
- Ghosh, A.K., K. Xi, V. Grum-Tokars, X. Xu and K. Ratia *et al.*, 2007. Structure-based design, synthesis and biological evaluation of peptidomimetic SARS-CoV 3CLpro inhibitors. *Bioorganic Med. Chem. Lett.*, 17: 5876-5880. PMID: 17855091
- Goetz, D.H., Y. Choe, E. Hansell, Y.T. Chen and M. McDowell *et al.*, 2007. Substrate specificity profiling and identification of a new class of inhibitor for the major protease of the SARS coronavirus. *Biochemistry*, 46: 8744-8752. PMID: 17605471
- Graham, R.L., M.M. Becker, L.D. Eckerle, M. Bolles and M.R. Denison *et al.*, 2012. A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease. *Nature Med.*, 18: 1820-1826. DOI:10.1038/nm.2972
- Groneberg, D.A., S.M. Poutanen, D.E. Low, H. Lode and T. Welte *et al.*, 2005. Treatment and vaccines for severe acute respiratory syndrome. *Lancet Infect. Dis.*, 5: 147-155. DOI: 10.1016/S1473-3099(05)01307-1
- Guan, Y., B.J. Zheng, J.S.M. Peiris, Y.J. Guan and L.J. Zhang *et al.*, 2003. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. *Science*, 302: 276-278. DOI: 10.1126/science.1087139
- Haga, S., N. Nagata, N. Yamamoto T. Sata and N. Yamamoto *et al.*, 2010. TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds. *Antivir. Res.*, 85: 551-555. DOI: 10.1016/j.antiviral.2009.12.001
- Han, D.P., A. Penn-Nicholson and M.W. Cho, 2006. Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor. *Virology*, 350: 15-25. DOI: 10.1016/j.virol.2006.01.029
- He, R., A. Adonov, J. Cao, T. Cutts and E. Grudesky *et al.*, 2004. Potent and selective inhibition of SARS coronavirus replication by aurintricarboxylic acid. *Biochem. Biophys. Res. Commun.*, 320: 1199-1203. DOI: 10.1016/j.bbrc.2004.06.076
- Hoever, G. and L. Baltina, 2005. Antiviral activity of glycyrrhizic acid derivatives against SARS-coronavirus. *J. Med. Chem.*, 48: 1256-1259. DOI: 10.1021/jm0493008
- Hu, M.C., T. Jones, R.T. Kenney, D.L. Barnard and D.S. Burt *et al.*, 2007. Intranasal protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice. *Vaccine*, 25: 6334-6340. PMID: 17640780

- Imai, Y., K. Kuba, S. Rao Y. Huan and F. Guo *et al.*, 2005. Angiotensin-converting enzyme 2 protects from severe acute lung failure. *Nature*, 436: 112-116. DOI: 10.1038/nature03712
- Jang, K.J., N.R. Lee, W.S. Yeo, Y.J. Jeong and D.E. Kim *et al.*, 2008. Isolation of inhibitory RNA aptamers against Severe Acute Respiratory Syndrome (SARS) coronavirus NTPase/Helicase. *Biochem. Biophys. Res. Commun.*, 366: 738-744. DOI: 10.1016/j.bbrc.2007.12.020
- Jaume, M., M.S. Yip, C.Y. Cheung, H.L. Leung and P.H. Li *et al.*, 2011. Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH-and cysteine protease-independent FcγR pathway. *J. Virol.*, 85: 10582-10597. DOI: 10.1128/JVI.00671-11
- Kaeppler, U., N. Stiefl, A. Breuning, R. Vicik and C. Schmuck *et al.*, 2005. A new lead for nonpeptidic active-site-directed inhibitors of the severe acute respiratory syndrome coronavirus main protease discovered by a combination of screening and docking methods. *J. Med. Chem.*, 48: 6832-6842. DOI: 10.1021/jm0501782
- Kam, Y.W., F. Kien, A. Roberts, Y.C. Cheung and L. Vogel *et al.*, 2007. Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcγRII-dependent entry into B cells *in vitro*. *Vaccine*, 25: 729-740. DOI: 10.1016/j.vaccine.2006.08.011
- Kao, R.Y., A.P. To, L.W.Y. Ng, W.H.W. Tsui and T.S.W. Lee *et al.*, 2004. Characterization of SARS-CoV main protease and identification of biologically active small molecule inhibitors using a continuous fluorescence-based assay. *FEBS Lett.*, 576: 325-330. DOI: 10.1016/j.febslet.2004.09.026
- Keum, Y.S. and Y.J. Jeong, 2012. Development of chemical inhibitors of the SARS coronavirus: Viral helicase as a potential target. *Biochem. Pharmacol.*, 84: 1351-1358. DOI: 10.1016/j.bcp.2012.08.012
- Keyaerts, E., L. Vijgen, P. Maes, J. Neyts and M.V. Ransst *et al.*, 2004. *In vitro* inhibition of severe acute respiratory syndrome coronavirus by chloroquine. *Biochem. Biophys. Res. Commun.*, 323: 264-268. DOI: 10.1016/j.bbrc.2004.08.085
- Ksiazek, T.G., D. Erdman, D. Erdman, C.S. Goldsmith and S.R. Zaki *et al.*, 2003. A novel coronavirus associated with severe acute respiratory syndrome. *New England J. Med.*, 348: 1953-1966. DOI: 10.1056/NEJMoa030781
- Kuo, C.J., H.G. Liu, Y.K. Lo, C.M. Seong and K.I. Lee *et al.*, 2009. Individual and common inhibitors of coronavirus and picornavirus main proteases. *FEBS Lett.*, 583: 549-555. DOI: 10.1016/j.febslet.2008.12.059
- Lai, S.T., 2005. Treatment of severe acute respiratory syndrome. *Eur. J. Clin. Microbiol. Infect. Dis.*, 24: 583-591. PMID: 16172857
- Lamirande, E.W., M.L. DeDiego, A. Roberts, J.P. Jackson and E. Alvarez *et al.*, 2008. A live attenuated severe acute respiratory syndrome coronavirus is immunogenic and efficacious in golden syrian hamsters. *J. Virol.*, 82: 7721-7724. DOI: 10.1128/JVI.00304-08
- Lang, J., N. Yang, J. Deng, K. Liu and P. Yang *et al.*, 2011. Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans. *PLoS One*, 6: e23710-e23710. DOI: 10.1371/journal.pone.0023710
- Lau, C.W.A., L.K.Y. So and L.Y.C. Yam, 2006. Response to published article. *J. Infect.*, 52: 309-310. DOI: 10.1016/j.jinf.2005.08.004
- Lee, C.C., C.J. Kuo, M.F. Hsu, P.H. Liang and J.M. Fang *et al.*, 2007. Structural basis of mercury-and zinc-conjugated complexes as SARS-CoV 3C-like protease inhibitors. *FEBS Lett.*, 581: 5454-5458. DOI: 10.1016/j.febslet.2007.10.048
- Lee, C.C., C.J. Kuo, Y.C. Tsui, H.C. Chen and P.H. Liang *et al.*, 2009. Structural basis of inhibition specificities of 3C and 3C-like proteases by zinc-coordinating and peptidomimetic compounds. *J. Biol. Chem.*, 284: 7646-7655. DOI: 10.1074/jbc.M807947200
- Lee, T.W., M.M. Cherney, K.E. James, J.C. Powers and M.N.G. James *et al.*, 2005. Crystal structures of the main peptidase from the SARS coronavirus inhibited by a substrate-like aza-peptide epoxide. *J. Mol. Biol.*, 353: 1137-1151. DOI: 10.1016/j.jmb.2005.09.004
- Li, T. and Y. Zhang, L. Fu, C. Yu and X. Li *et al.*, 2005a. siRNA targeting the leader sequence of SARS-CoV inhibits virus replication. *Gene Therapy*, 12: 751-761. DOI: 10.1038/sj.gt.3302479
- Li, W., Z. Shi, L.F. Wang, W. Ren and J.H. Epstein *et al.*, 2005b. Bats are natural reservoirs of SARS-like coronaviruses. *Science*, 310: 676-679. DOI: 10.1126/science.1118391
- Liang, P.H., 2006. Characterization and inhibition of SARS-coronavirus main protease. *Curr. Topics Med. Chem.*, 6: 361-376. DOI: 10.2174/156802606776287090

- Lin, C.W., F.J. Tsai, C.H. Tsai, C.C. Lai and L. Wan *et al.*, 2005. Anti-SARS coronavirus 3C-like protease effects of *Isatis indigotica* root and plant-derived phenolic compounds. *Antivir. Res.*, 68: 36-42. DOI: 10.1016/j.antiviral.2005.07.002
- Lin, J.T., J.S. Zhang, N. Wang, J.T. Chen and X. Chen *et al.*, 2007. Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine. *Antivir. Ther.*, 12: 1107-1113. PMID: 18018769
- Lu, G. and D. Liu, 2012. SARS-like virus in the Middle East: A truly bat-related coronavirus causing human diseases. *Protein Cell*, 3: 803-805. DOI: 10.1007/s13238-012-2811-1
- Ma, X.Z., A. Bartczak, J. Zhang, R. Khattar and M.F. Liu *et al.*, 2010. Proteasome inhibition in vivo promotes survival in a lethal murine model of severe acute respiratory syndrome. *J. Virol.*, 84: 12419-12428. DOI: 10.1128/JVI.01219-10
- Martin, J.E., M.K. Loudera, L.A. Holmana, I.J. Gordona and M.E. Enama *et al.*, 2008. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. *Vaccine*, 26: 6338-6343. DOI: 10.1016/j.vaccine.2008.09.026
- Millet, J.K., F. Kien, C.Y. Heung, Y.L. Siu and W.L. Chan *et al.*, 2012. Ezrin Interacts with the SARS coronavirus spike protein and restrains infection at the entry stage. *PLoS One*, 7: e49566-e49566. DOI: 10.1371/journal.pone.0049566
- Morgenstern, B., M. Michaelis, P.C. Baer and H.W. Doerr, 2005. Ribavirin and interferon- β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. *Biochem. Biophys. Res. Commun.*, 326: 905-908. DOI: 10.1016/j.bbrc.2004.11.128
- Mukherjee, P., F. Shah, P. Desai and M. Avery 2011. Inhibitors of SARS-3CL^{pro}: Virtual screening, biological evaluation and molecular dynamics simulation studies. *J. Chem. Inform. Model.*, 51: 1376-1392. DOI: 10.1021/ci1004916
- Mukherjee, P., P. Desai, L. Ross, E.L. White and M.A. Avery *et al.*, 2008. Structure-based virtual screening against SARS-3CL(pro) to identify novel non-peptidic hits. *Bioorganic Med. Chem.*, 16: 4138-4149. DOI: 10.1016/j.bmc.2008.01.011
- Napoli, P.D., P.D. Giovanni, M.A. Gaeta, A.A. Taccardi, 2007. Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: A post hoc analysis of the villa pini d'abruzzo trimetazidine trial. *J. Cardiovascular Pharmacol.*, 50: 585-589. DOI: 10.1097/FJC.0b013e31814fa9cb
- Neuman, B.W. and D.A. Stein, A.D. Kroeker, M.J. Churchill and A.M. Kim *et al.*, 2005. Inhibition, escape and attenuated growth of severe acute respiratory syndrome coronavirus treated with antisense morpholino oligomers. *J. Virol.*, 79: 9665-9676. DOI: 10.1128/JVI.79.15.9665-9676.2005
- Nguyen, T.T., H.J. Ryu, S.H. Lee, S. Hwang and V. Breton *et al.*, 2011. Virtual screening identification of novel severe acute respiratory syndrome 3C-like protease inhibitors and in vitro confirmation. *Bioorganic Med. Chem. Lett.*, 21: 3088-3091. DOI: 10.1016/j.bmcl.2011.03.034
- Nguyen, T.T., H.J. Woo, H.K. Kang, V.D. Nguyen and Y.M. Kim *et al.*, 2012. Flavonoid-mediated inhibition of SARS coronavirus 3C-like protease expressed in *Pichia pastoris*. *Biotechnol. Lett.*, 34: 831-838. DOI: 10.1007/s10529-011-0845-8
- Ni, L., J. Zhu, J. Zhanga, M. Yana and G.F. Gao *et al.*, 2005. Design of recombinant protein-based SARS-CoV entry inhibitors targeting the heptad-repeat regions of the spike protein S2 domain. *Biochem. Biophys. Res. Commun.*, 330: 39-45. DOI: 10.1016/j.bbrc.2005.02.117
- Olsen, C.W., W.V. Corapi, R.H. Jacobson R.A. Simkins and L.J. Saif *et al.*, 1993. Identification of antigenic sites mediating antibody-dependent enhancement of feline infectious peritonitis virus infectivity. *J. General Virol.*, 74: 745-749. DOI: 10.1099/0022-1317-74-4-745
- Pfefferle, S., J. Schopf, M. Kögl, C.C. Friedel and M.A. Müller *et al.*, 2011. The SARS-coronavirus-host interactome: Identification of cyclophilins as target for pan-coronavirus inhibitors. *PLoS Pathogens*, 7: e1002331-e1002331. DOI: 10.1371/journal.ppat.1002331
- Plewczynski, D., M. Hoffmann, M.V. Grotthuss, K. Ginalski and L. Rychewski *et al.*, 2007. In silico prediction of SARS protease inhibitors by virtual high throughput screening. *Chem. Biol. Drug Des.*, 69: 269-279. PMID: 17461975
- Qin, Z.L., P. Zhao, X.L. Zhang, J.G. Yu and M.M. Cao *et al.*, 2004. Silencing of SARS-CoV spike gene by small interfering RNA in HEK 293T cells. *Biochem. Biophys. Res. Commun.*, 324: 1186-1193. PMID: 15504339
- Ramajayam, R., K.P. Tan and P.H. Liang, 2011. Recent development of 3C and 3CL protease inhibitors for anti-coronavirus and anti-picornavirus drug discovery. *Biochem. Soc. Trans.*, 39: 1371-1375. DOI: 10.1042/BST0391371

- Ramajayam, R., K.P. Tan, H.G. Liub and P.H. Liang, 2010. Synthesis, docking studies and evaluation of pyrimidines as inhibitors of SARS-CoV 3CL protease. *Bioorganic Med. Chem. Lett.*, 20: 3569-3572. DOI: 10.1016/j.bmcl.2010.04.118
- Ratia, K., S. Pegan, K. Sleeman, M. Coughlin and S. Baliji *et al.*, 2008. A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. *Proc. Natl. Acad. Sci. USA.*, 105: 16119-16124. DOI: 10.1073/pnas.0805240105
- Regnier, T., D. Sarma, K. Hidaka, U. Bacha and E. Freire *et al.*, 2009. New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CL(pro) inhibitors. *Bioorganic Med. Chem. Lett.*, 19: 2722-2727. DOI: 10.1016/j.bmcl.2009.03.118
- Roberts, A., E.W. Lamirande, L. Vogel, J.P. Jackson and C.D. Paddock *et al.*, 2008. Animal models and vaccines for SARS-CoV infection. *Virus Res.*, 133: 20-32. PMID: 17499378
- Roper, R.L. and K.E. Rehm, 2009. SARS vaccines: Where are we? *Expert Rev. Vaccines*, 8: 887-898. PMID: 19538115
- Rota, P.A., M.S. Oberste, W.A. Nix, R. Campagnoli and J.P. Icenogle *et al.*, 2003. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. *Science*, 300: 1394-1399. DOI: 10.1126/science.1085952
- Ruan, Y.J., C.L. Wei, H. Thoreau, S.T. Su and J.M. Chia *et al.*, 2003. Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection. *Lancet*, 361: 1779-1785. PMID: 12781537
- Ryu, Y.B., S.J. Park, Y.M. Kim, J.Y. Lee and W.D. Seo *et al.*, 2010. SARS-CoV 3CLpro inhibitory effects of quinone-methide triterpenes from *Tripterygium regelii*. *Bioorganic and Med. Chem. Lett.*, 20: 1873-1876. DOI: 10.1016/j.bmcl.2010.01.152
- Saijo, M., S. Morikawa, S. Fukushi, T. Mizutani and H. Hasegawa *et al.*, 2005. Inhibitory effect of mizoribine and ribavirin on the replication of Severe Acute Respiratory Syndrome (SARS)-associated coronavirus. *Antivir. Res.*, 66: 159-163. PMID: 15911031
- Sainz, B.J., E.C. Mossel, W.R. Gallaher, W.C. Wimley and C.J. Peters *et al.*, 2006. Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein. *Virus Res.*, 120: 146-155. PMID: 16616792
- Schwarz, S. and K. Wang, 2011. Emodin inhibits current through SARS-associated coronavirus 3a protein. *Antiviral Res.*, 90: 64-69. DOI: 10.1016/j.antiviral.2011.02.008
- See, R.H., A.N. Zakhartchouk, M. Petric, D.J. Lawrence and C.P. Mok *et al.*, 2006. Comparative evaluation of two Severe Acute Respiratory Syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. *J. General Virol.*, 87: 641-650. PMID: 16476986
- See, R.H., M. Petric, D.J. Lawrence, C.P. Mok and T. Rowe *et al.*, 2008. Severe acute respiratory syndrome vaccine efficacy in ferrets: Whole killed virus and adenovirus-vectored vaccines. *J. Gen. Virol.*, 89: 2136-2146. DOI: 10.1099/vir.0.2008/001891-0
- Shao, Y.M., W.B. Yang, T.H. Kuo, K.C. Tsai and C.H. Lin *et al.*, 2008. Design, synthesis and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease. *Bioorganic Med. Chem.*, 16: 4652-4660. DOI: 10.1016/j.bmc.2008.02.040
- Shim, B.S., K. Stadler, H.H. Nguyen, C.H. Yun and D.W. Kim *et al.*, 2012. Sublingual immunization with recombinant adenovirus encoding SARS-CoV spike protein induces systemic and mucosal immunity without redirection of the virus to the brain. *Virol. J.*, 19: 215-215. DOI: 10.1186/1743-422X-9-215
- Simmons, G., D.N. Gosalia, A.J. Rennekamp, J.D. Reeves and S.L. Diamond *et al.*, 2005. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. *Proc. Natl. Acad. Sci. USA.*, 102: 11876-11881. DOI: 10.1073/pnas.0505577102
- Smith, S.B., W. Dampier, A. Tozeren, J.R. Brown and M. Magid-Slav, 2012. Identification of common biological pathways and drug targets across multiple respiratory viruses based on human host gene expression analysis. *PloS One*, 7: e33174-e33174. DOI: 10.1371/journal.pone.0033174
- Stockman, L.J., R. Bellamy and P. Garner, 2006. SARS: Systematic review of treatment effects. *PLoS Med.*, 3: e343- e343. DOI:10.1371/journal.pmed.0030343
- Struck, A.W., M. Axmann, S. Pfefferle, C. Drosten and B. Meyera, 2012. A hexapeptide of the receptor-binding domain of SARS corona virus spike protein blocks viral entry into host cells via the human receptor ACE2. *Antivir. Res.*, 94: 288-296. DOI: 10.1016/j.antiviral.2011.12.012

- Subbarao, K., J. McAuliffe, L. Vogel, G. Fahle and S. Fischer *et al.*, 2004. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. *J. Virol.*, 78: 3572-3577. DOI: 10.1128/JVI.78.7.3572-3577.2004
- Sunwoo, H.H., A. Palaniyappan, A. Ganguly, P.K. Bhatnagar and D. Das *et al.*, 2012. Quantitative and sensitive detection of the SARS-CoV spike protein using bispecific monoclonal antibody-based enzyme-linked immunoassay. *J. Virol. Meth.*, 187: 72-78 DOI: 10.1016/j.jviromet.2012.09.006
- Tang, Q. and B. Li, 2008. Application of siRNA against SARS in the rhesus macaque model. *Methods Mol. Biol.*, 442: 139-158. DOI: 10.1007/978-1-59745-191-8_11
- Tseng, C.T., E. Sbrana, N. Iwata-Yoshikawa, P.C. Newman and T. Garron *et al.*, 2012. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. *PloS One*, 7: e35421-e35421. DOI: 10.1371/journal.pone.0035421
- Tsui, S.K., S.S. Chim and Y.M.D. Lo, 2003. Coronavirus genomic-sequence variations and the epidemiology of the severe acute respiratory syndrome. *New England J. Med.*, 349: 187-188. DOI: 10.1056/NEJM200307103490216
- Ujike, M., H. Nishikawa, A. Otake, N. Yamamoto and N. Yamamoto *et al.*, 2008. Heptad repeat-derived peptides block protease-mediated direct entry from the cell surface of severe acute respiratory syndrome coronavirus but not entry via the endosomal pathway. *J. Virol.*, 82: 588-592. DOI: 10.1128/JVI.01697-07
- Verschuere, K.H., K. Pumpor, S. Anemüller, S. Chen and J.R. Mesters *et al.*, 2008. A structural view of the inactivation of the SARS coronavirus main proteinase by benzotriazole esters. *Chem. Biol.*, 15: 597-606. DOI: 10.1016/j.chembiol.2008.04.011
- Vincent, M.J., E. Bergeron, S. Benjannet, B.R. Erickson and P.E. Rollin *et al.*, 2005. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. *Virology*, 2: 69-69. DOI: 10.1186/1743-422X-2-69
- Wang, S.Q., Q.S. Du, K. Zhao, A.X. Li and D.Q. Wei *et al.*, 2007. Virtual screening for finding natural inhibitor against cathepsin-L for SARS therapy. *Amino Acids*, 33: 129-135. PMID: 16998715
- Weingartl, H., M. Czub, S. Czub, J. Neufeld and P. Marszal *et al.*, 2004. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. *J. Virol.*, 78: 12672-12676. DOI: 10.1128/JVI.78.22.12672-12676
- Wu, C.J. and H.W. Huang, 2005. Inhibition of SARS-CoV replication by siRNA. *Antiviral Res.*, 65: 45-48. DOI: 10.1016/j.antiviral.2004.09.005
- Wu, C.J., J.T. Jan, C.M. Chen, H.P. Hsieh and D.R. Hwang *et al.*, 2004a. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. *Antimicrob. Agents Chemother.*, 48: 2693-2696. DOI: 10.1128/AAC.48.7.2693-2696.2004
- Wu, C.Y., J.T. Jan, S.H. Ma, C.J. Kuo and H.F. Juan *et al.*, 2004b. Small molecules targeting severe acute respiratory syndrome human coronavirus. *Proc. Natl. Acad. Sci. USA.*, 101: 10012-10017. DOI: 10.1073/pnas.0403596101
- Wu, X., G. Cheng, M. Wang, X. Zhou and L. He *et al.*, 2003. Establishment of a fluorescent polymerase chain reaction method for the detection of the SARS-associated coronavirus and its clinical application. *Chin. Med. J.*, 116: 988-990. PMID: 12890368
- Yam, W.C., K.H. Chan, Y. Guan, K.Y. Yuen and W.H. Seto *et al.*, 2003. Evaluation of reverse transcription-PCR assays for rapid diagnosis of severe acute respiratory syndrome associated with a novel coronavirus. *J. Clin. Microbiol.*, 41: 4521-4524. DOI: 10.1128/JCM.41.10.4521-4524.2003
- Yang, C.W. and Y.Z. Lee, I.J. Kang, D.L. Barnard and J.T. Jan *et al.*, 2010. Identification of phenanthroindolizines and phenanthroquinolizidines as novel potent anti-coronaviral agents for porcine enteropathogenic coronavirus transmissible gastroenteritis virus and human severe acute respiratory syndrome coronavirus. *Antiviral Res.*, 88: 160-168. DOI: 10.1016/j.antiviral.2010.08.009
- Yang, H., W. Xie, X. Xue, K. Yang and J. Ma *et al.*, 2005a. Design of wide-spectrum inhibitors targeting coronavirus main proteases. *PLoS Biol.*, 3: e324-e324. DOI: 10.1371/journal.pbio.003032
- Yang, N., J.A. Tanner, Z. Wang, J.D. Huang and B.J. Zheng *et al.*, 2007. Inhibition of SARS coronavirus helicase by bismuth complexes. *Chem. Commun.*, 42: 4413-4415. DOI: 10.1039/B709515E
- Yang, Z.Y., H.C. Werner, W.P. Kong, K. Leung and E. Traggiai *et al.*, 2005b. Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. *Proc. Natl. Acad. Sci. USA.*, 102: 797-801. DOI: 10.1073/pnas.0409065102
- Yang, Z.Y., W.P. Kong, Y. Huang, A. Roberts and B.R. Murphy, 2004. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. *Lett. Nature*, 428: 561-564. DOI: 10.1038/nature02463

- Yi, L., Z. Li, K. Yuan, X. Qu and J. Chen *et al.*, 2004. Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells. *J. Virol.*, 78: 11334-11339. DOI: 10.1128/JVI.78.20.11334-11339.2004
- Zakhartchouk, A.N., S. Viswanathan, J.B. Mahony, J. Gauldie and L.A. Babiuk *et al.*, 2005. Severe acute respiratory syndrome coronavirus nucleocapsid protein expressed by an adenovirus vector is phosphorylated and immunogenic in mice. *J. Gen. Virol.*, 86: 211-215. DOI: 10.1099/vir.0.80530-0
- Zhang, J., C. Huitema, C. Niuc, J. Yinc and M.N.G. James *et al.*, 2008. Aryl methylene ketones and fluorinated methylene ketones as reversible inhibitors for Severe Acute Respiratory Syndrome (SARS) 3C-like proteinase. *Bioorganic Chem.*, 36: 229-240. DOI: 10.1016/j.bioorg.2008.01.001
- Zhang, J., H.I. Pettersson, C. Huitema, C. Niu and J. Yin *et al.*, 2007. Design, synthesis and evaluation of inhibitors for severe acute respiratory syndrome 3C-like protease based on phthalhydrazide ketones or heteroaromatic esters. *J. Med. Chem.*, 50: 1850-1864. DOI: 10.1021/jm061425k
- Zhao, J. and S. Perlman, 2010. T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. *J. Virol.*, 84: 9318-9325. DOI: 10.1128/JVI.01049-10
- Zhao, J., C. Wohlford-Lenane, J. Zhao, E. Fleminga and T.E. Lane *et al.*, 2012. Intranasal treatment with Poly(I:C) protects aged mice from lethal respiratory virus infections. *J. Virol.*, 86: 11416-11424. DOI: 10.1128/JVI.01410-12
- Zhao, P. and Z.L. Qin, 2005. Small interfering RNA inhibits SARS-CoV nucleocapsid gene expression in cultured cells and mouse muscles. *FEBS Lett.*, 579: 2404-2410. DOI: 10.1016/j.febslet.2005.02.080
- Zhou, Y., J. Agudelo, D.H. Goetz, E. Hanselld and Y.T. Chen *et al.*, 2011. Inhibitors of SARS-CoV entry- Identification using an internally-controlled dual envelope pseudovirion assay. *Antiviral Res.*, 92: 187-194. DOI: 10.1016/j.antiviral.2011.07.016
- Zhuang, M. and H. Jiang, 2009. Procyanidins and butanol extract of Cinnamomi Cortex inhibit SARS-CoV infection. *Antiviral Res.*, 82: 73-81. DOI: 10.1016/j.antiviral.2009.02.001